SynthesisBMC surgery2026
Psoriasis outcomes following metabolic bariatric surgery - a systematic review of the literature.
Synthesis in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tackling obesity's impact: the need to address metabolic syndrome in osteoarthritis management.Future science OA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic bariatric surgery (MBS) has been associated with improved clinical outcomes of psoriasis, yet evidence-based guidelines remain unclear. This systematic review aims to analyze current evidence on psoriasis outcomes following MBS and identify factors influencing clinical response.
methodsA systematic literature search of PubMed®, Scopus, and Google Scholar® was conducted according to PRISMA guidelines. Data extracted included study design, patient demographics, type of MBS, weight loss, and psoriasis outcomes assessed by Psoriasis Area Severity Index (PASI), percentage of affected body surface area (%ABSA), nail involvement, Dermatology Life Quality Index (DLQI), and treatment requirements. Subgroup analysis compared gastric bypass with non-bypass procedures. Due to heterogeneity, a qualitative synthesis was performed.
resultsSix studies involving 447 patients were included. Demographic data were available for 159 patients (mean age 46.9 years, mean BMI 43.8 kg/m²). Pooled BMI reduction was 11.0 ± 3.3 kg/m². Baseline therapies included systemic in 53%, topical in 44%, and phototherapy in 5%. After surgery, systemic therapy decreased to 34%, topical to 39%, and 29% required no treatment. DLQI decreased from 14.9 to 5.0, %ABSA from 5.7 to 1.7, PASI from 3.6 to 1.2, and nail involvement from 43.8% to 21.9% (p < 0.05). Overall, 69.5% of individuals demonstrated improvement or remission of psoriasis, primarily defined by reduced or discontinued treatment. Improvement or remission was noted in 80% of gastric bypass and 10% after non-bypass surgery, with higher PASI reduction after bypass (ΔPASI 2.32 vs 1.67). Factors related to improved clinical response included greater excess weight loss, older age, Roux-en-Y gastric bypass and absence of family history of psoriasis.
conclusionsMBS may improve psoriasis severity, quality of life, and treatment requirements, but current evidence is uncertain. Weight loss magnitude, type of MBS and patient characteristics might affect clinical response of psoriasis. Further prospective studies are required to establish personalized management among individuals with psoriasis and obesity.
trial registrationRegistration of systematic review: PROSPERO database (UIN: CRD420251108229).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.